<DOC>
	<DOC>NCT00884507</DOC>
	<brief_summary>This 4 arm study will assess the efficacy and safety of RO5313534 (MEM3454) versus placebo added to donepezil, in patients with mild to moderate Alzheimer's disease. Following a screening period, patients will be randomized to one of 4 treatments (placebo, or RO5313534 1mg, 5mg or 15mg po daily) with background therapy of donepezil (5mg or 10mg).The anticipated time on study treatment is 6 months, and the target sample size is 100-500 individuals.</brief_summary>
	<brief_title>A Study of RO5313534 as Add-on to Donepezil Treatment in Patients With Mild to Moderate Alzheimer's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<criteria>adult patients, &gt;/=50 years of age; probable Alzheimer's disease; MMSE score at screening of 1322; under stable donepezil treatment given at a fixed dose of 5 or 10mg daily for &gt;=4 months prior to baseline; not requiring nursing home care, but looked after by a caregiver/carer. dementia due to condition other than Alzheimer's disease; other significant neurological disorder; untreated/nonstabilized major depressive disorder; bipolar disorder, schizophrenia, or any other serious psychiatric condition.</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>